Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -108.08% | 1,588.08% | -93.41% | 503.82% | 12.55% |
| Total Depreciation and Amortization | -4.58% | 7.04% | 4.30% | -2.18% | -6.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.05% | -29.20% | 190.59% | -278.86% | 548.03% |
| Change in Net Operating Assets | 204.76% | -328.80% | -110.70% | 203.82% | 274.00% |
| Cash from Operations | 1,308.43% | 6.82% | -103.13% | 383.45% | 4,871.51% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8,724.33% | 100.59% | -176.74% | -218.26% | 92.95% |
| Cash from Investing | 8,844.39% | 100.59% | -176.48% | -218.37% | 95.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -50.61% | 75.54% | -- | -100.00% | -87.73% |
| Repurchase of Common Stock | -193.99% | -191.89% | -34.79% | 42.45% | -65.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -274.04% | -272.75% | 20.48% | 41.10% | -133.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,826.64% | 93.50% | -162.55% | 135.27% | 405.01% |